Nisa Investment Advisors
EIGR

Nisa Investment Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Nisa Investment Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4
Closed – – 2890
2023
Q1 		$0 Buy
+4
New +$186 ﹤0.01% 2772
2021
Q4 		– Sell
-215
Closed -$43 – 2344
2021
Q3 		$43 Hold
215
– – ﹤0.01% 1970
2021
Q2 		$55 Buy
215
+22
+11% +$5.49K ﹤0.01% 1917
2021
Q1 		$51 Hold
193
– – ﹤0.01% 1977
2020
Q4 		$71K Buy
+193
New +$55.4K ﹤0.01% 1880

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Nisa Investment Advisors's EIGR Position: Q2 2023 in Review

Nisa Investment Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2023, closing a stake of 4 shares.

Nisa Investment Advisors first reported a position in EIGR in Q4 2020 and held it in 5 quarters. The position peaked at $71K in Q4 2020. 66 funds tracked by Wall St. Rank hold EIGR as of Q2 2023.

  • Nisa Investment Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Nisa Investment Advisors sold 4 Eiger BioPharmaceuticals, Inc. shares in Q2 2023.
  • Nisa Investment Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2020 and held it in 5 quarters.
  • Nisa Investment Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $71K in Q4 2020.
  • 66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2023.

Based on Nisa Investment Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.